ReviewCancers2022
Updated Prognostic Factors in Localized NSCLC.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Mastering CT-based radiomic research in lung cancer: a practical guide from study design to critical appraisal.The British journal of radiology · 2025Guideline
- Development and Validation of a Prognostic Nomogram for Lung Adenocarcinoma: A Population-Based Study.Journal of healthcare engineering · 2022Trial
- Cost-effectiveness analysis of tepotinib vs capmatinib as subsequent therapy in MET exon 14-mutated non-small-cell lung cancer.Lung cancer management · 2026Review
- Multiple Options, One Objective: Clearer Decisions in Resectable Non-Small Cell Lung Cancer.Cancers · 2026Review
- Clinicopathological features and therapeutic advances in primary pulmonary lymphoepithelioma-like carcinoma (Review).Oncology letters · 2026Review
- Prognostic Factors of Chinese Non-small Cell Lung Cancer Patients Receiving Best Supportive Care.Cureus · 2026Article
- Correlation between Cx37 and ALK expression and prognosis of elderly patients with non-small cell lung cancer.Journal of cardiothoracic surgery · 2026Article
- Construction of a postoperative disease-free survival prediction model for non-small cell lung cancer patients based on dual-energy computed tomography parameters and blood inflammatory indicators.Translational cancer research · 2026Article
- Breaking: The New 9Thoracic research and practice · 2026Article
- Sex-based survival disparities in patients with stage I-III non-small cell lung cancer vary by treatment modality.Frontiers in oncology · 2026Article
- Externally validated explainable machine learning for postoperative recurrence prediction in early-stage NSCLC.Frontiers in oncology · 2026Article
- Immune checkpoint crosstalk: CTLA-4/CD80 engagement as a predictor of anti-PD-1/PD-L1 therapy outcome in NSCLC.Frontiers in immunology · 2026Article
- Prognostic performance of a novel multiplex circulating tumor DNA assay for lung cancer outcomes.Therapeutic advances in medical oncology · 2026Article
- Assessing clinician performance using a multi-modality clinical decision-support system for lung cancer prognostication.Scientific reports · 2025Article
- LncRNA-Mediated miR-145 Sponging Drives FN1 and CCND1 Expression: Prognostic and Therapeutic Targets in NSCLC.Biomolecules · 2025Article
- AI-powered spatial cell phenomics enhances risk stratification in non-small cell lung cancer.Nature communications · 2025Article
- Prognostic Factors and Survival Data of Stage I Lung Cancer: A Single-Center Experience.Journal of clinical practice and research · 2025Article
- Free-floating patient-derived organotypic tumor spheroids (PDOTS) from non-small cell lung cancer (NSCLC) tumors: a versatile tool for personalized testing of chemotherapeutic drugs.Research in pharmaceutical sciences · 2025Article
- Inflammation-Based Prognostication in Advanced-Stage NSCLC: A Retrospective Cohort Study.Cancers · 2025Article
- Co-expression of a truncated TGFβ receptor II in c-Met CAR T cells enhances antitumor activity against lung adenocarcinoma.Scientific reports · 2025Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is the most common cause of cancer mortality worldwide, and non-small cell lung cancer (NSCLC) represents 80% of lung cancer subtypes. Patients with localized non-small cell lung cancer may be considered for upfront surgical treatment. However, the overall 5-year survival rate is 59%. To improve survival, adjuvant chemotherapy (ACT) was largely explored and showed an overall benefit of survival at 5 years < 7%. The evaluation of recurrence risk and subsequent need for ACT is only based on tumor stage (TNM classification); however, more than 25% of patients with stage IA/B tumors will relapse. Recently, adjuvant targeted therapy has been approved for EGFR-mutated resected NSCLC and trials are evaluating other targeted therapies and immunotherapies in adjuvant settings. Costs, treatment duration, emergence of resistant clones and side effects stress the need for a better selection of patients. The identification and validation of prognostic and theranostic markers to better stratify patients who could benefit from adjuvant therapies are needed. In this review, we report current validated clinical, pathological and molecular prognosis biomarkers that influence outcome in resected NSCLC, and we also describe molecular biomarkers under evaluation that could be available in daily practice to drive ACT in resected NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.